Relmada Therapeutics, Inc. (RLMD)
4.13
-0.18
(-4.18%)
USD |
NASDAQ |
Jan 12, 16:00
4.13
0.00 (0.00%)
After-Hours: 20:00
Relmada Therapeutics Research and Development Expense (Quarterly): 4.036M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amicus Therapeutics, Inc. | 23.42M |
| Invivyd, Inc. | 8.046M |
| Arcellx, Inc. | 35.09M |
| Puma Biotechnology, Inc. | 15.91M |
| NovaBay Pharmaceuticals, Inc. | -- |